Clinical Scorecard: Efficacy and Safety of Omalizumab in Chinese Pediatric Patients Under 12 with Chronic Urticaria: A Case Series Analysis

At a Glance

Key Highlights

• All 13 pediatric patients showed rapid clinical improvement within one week after initial omalizumab dose.
• Significant reduction in median Urticaria Activity Score over 7 days (UAS7) from 20.0 to 4.0 at week 4 (p=0.001).
• No adverse events reported across 74 administered doses, indicating excellent safety and tolerability.

Guideline-Based Recommendations

Diagnosis

• Chronic urticaria diagnosis based on presence of wheals and/or angioedema for more than 6 weeks.
• Use Urticaria Activity Score over 7 days (UAS7) to assess disease activity.

Management

• First-line treatment: second-generation H1-antihistamines at licensed or high doses.
• Second-line treatment: omalizumab recommended for patients aged ≥12 years with inadequate response to antihistamines; this study supports use in children under 12 with refractory CU.
• Omalizumab administered as 150 mg subcutaneous injection.

Monitoring & Follow-up

• Monitor UAS7 scores to evaluate treatment response; well-controlled disease defined as UAS7 ≤6 at week 4.
• Monitor for adverse events during and after omalizumab administration.

Risks

• No adverse events reported in this study; however, patients with autoimmune disorders or on immunosuppressants were excluded.
• Potential residual mild disease activity in patients with high baseline UAS7 and comorbid allergic rhinitis.

Patient & Prescribing Data

13 Chinese children under 12 years with refractory chronic urticaria unresponsive to high-dose antihistamines

Rapid symptom control achieved within one week; oral antihistamines discontinued within 4 weeks; 84.6% achieved well-controlled disease by week 4; excellent safety profile with no adverse events reported.

Clinical Best Practices

• Consider omalizumab as a second-line therapy for children under 12 with refractory chronic urticaria after failure of high-dose antihistamines.
• Use UAS7 scoring to objectively assess disease severity and treatment response.
• Obtain informed consent from legal guardians prior to omalizumab administration.
• Exclude patients with autoimmune disorders or on immunosuppressive therapies when considering omalizumab.
• Monitor patients closely for clinical improvement and adverse events during treatment.

Related Resources & Content

• EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
• Prevalence and characteristics of chronic urticaria in children
• Efficacy of omalizumab in chronic inducible urticaria